Health-related quality-of-life measurement in hypertension -: A review of randomised controlled drug trials

被引:14
作者
Côte, I
Grégoire, JP
Moisan, J
机构
[1] Univ Laval, Fac Pharm, Laval, PQ, Canada
[2] Univ Laval, Epidemiol Res Grp, Laval, PQ, Canada
关键词
D O I
10.2165/00019053-200018050-00003
中图分类号
F [经济];
学科分类号
02 ;
摘要
In hypertension, tolerability of drug treatment is important because individuals may see the use of antihypertensive medications as more troubling than their seemingly symptomless disease. This may result in noncompliance and ineffectual long term treatment. In the past 15 years, new antihypertensive medications have been marketed on the basis of the advantages they offer with regard to adverse effects and the unavoidable impact of such adverse effects on a person's quality of life. When related to health, quality of life refers to the physical, psychological and social dimensions of health that are influenced by a person's experiences, beliefs, expectations and perceptions. To measure this concept, many instruments, either generic or specific, may be used. The purpose of this study is to describe, by way of a critical review of the literature, the instruments that are most often used in the measurement of health-related quality of life (HR-QOL) in people using antihypertensive drug treatments. We carried out a search of the literature published in English in the period January 1966 to July 2000, looking for randomised controlled trials of antihypertensive drugs. Using the Medline database, we included 77 papers in our review. Our main finding suggests that HR-QOL changes associated with antihypertensive treatment are measured with many different instruments. In almost all studies, at least 1 instrument specific to a health dimension was used, whereas not many used a generic instrument only. The most commonly measured HR-QOL dimensions were cognitive function, symptomatic well-being, sexual function, psychological well-being, sleep dysfunction, social participation and general health perception. Since the choice of dimensions to measure depends not only on the disease but also on the drug, this review adds further evidence that a generic instrument as well as a preference measurement should be added to a specific instrument.
引用
收藏
页码:435 / 450
页数:16
相关论文
共 104 条
[81]   Analysis of adverse effects among patients with essential hypertension receiving an ACE inhibitor or a beta-blocker [J].
Rosenthal, J ;
Bahrmann, H ;
Benkert, K ;
Baumgart, P ;
Bonner, G ;
Klein, G ;
Neiss, A ;
Schnelle, K ;
Frohlich, ED .
CARDIOLOGY, 1996, 87 (05) :409-414
[82]  
STEINER SS, 1990, J HUM HYPERTENS, V4, P217
[83]  
SUNDAR S, 1991, ACTA CARDIOL, V46, P227
[84]   Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough [J].
Tanser, PH ;
Campbell, LM ;
Carranza, J ;
Karrash, J ;
Toutouzas, P ;
Watts, R .
AMERICAN JOURNAL OF HYPERTENSION, 2000, 13 (02) :214-218
[85]  
TAYLOR M, 1991, CLIN EXP HYPERTENS A, V13, P189
[86]   Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients [J].
Tedesco, MA ;
Ratti, G ;
Mennella, S ;
Manzo, G ;
Grieco, M ;
Rainone, AC ;
Iarussi, D ;
Iacono, A .
AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (11) :1130-1134
[88]   ASSESSMENT OF QUALITY-OF-LIFE BY PATIENT AND SPOUSE DURING ANTIHYPERTENSIVE THERAPY WITH ATENOLOL AND NIFEDIPINE GASTROINTESTINAL THERAPEUTIC SYSTEM [J].
TESTA, MA ;
HOLLENBERG, NK ;
ANDERSON, RB ;
WILLIAMS, GH .
AMERICAN JOURNAL OF HYPERTENSION, 1991, 4 (04) :363-373
[89]   QUALITY-OF-LIFE AND ANTIHYPERTENSIVE THERAPY IN MEN - A COMPARISON OF CAPTOPRIL WITH ENALAPRIL [J].
TESTA, MA ;
ANDERSON, RB ;
NACKLEY, JF ;
HOLLENBERG, NK .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (13) :907-913
[90]   Current concepts - Assessment of quality-of-life outcomes [J].
Testa, MA ;
Simonson, DC .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (13) :835-840